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Abstract
Background: Local anesthetics are an important component of perioperative pain management, but the duration
of action of available products is limited. We hypothesized that a single local infiltration of a novel bupivacaine
liposome injectable suspension (AT-003) would provide clinically effective analgesia over a 72-h period.
In a masked, randomized, placebo-controlled, multi-center pilot field study, dogs undergoing lateral retinacular
suture placement for cranial cruciate insufficiency were randomly assigned to surgical site infiltration with AT-003
(5.3 mg/kg) or an equivalent volume of saline. Infiltration of the surgical site was done prior to closure. Primary
outcome measure was the Glasgow Composite Measure Pain Scale (CMPS-SF) assessed prior to surgery and at
2, 4, 8, 12, 24, 30, 36, 48, 54, 60 and 72 h following surgery by trained individuals. Provision for rescue analgesia was
employed. Repeated measures analysis of variance were utilized to test for possible differences between treatment
groups and a success/failure analysis was also employed, based on the need for rescue analgesia.
Results: Forty-six dogs were enrolled and evaluated. For CMPS-SF scores there was a significant overall treatment
effect (p = 0.0027) in favor of AT-003. There were significantly more successes in the AT-003 group compared to
placebo over each time period (p = 0.0001 for 0–24 h, p = 0.0349 for 0–48 h, and p = 0.0240 for 0-72 h). No
significant adverse events were seen.
Conclusions: AT-003 (bupivacaine liposome injectable suspension) provided measurable local analgesia over a 72-h
period following post-stifle surgery surgical site tissue infiltration. Further work is indicated to develop this product
for clinical use.
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Background
Perioperative analgesia has become recognized as an im-
portant ethical responsibility of veterinarians over the
last three decades. Clinical evidence in dogs indicates
that multimodal analgesia provides the most effective
relief from postoperative pain [1]. One of the most ef-
fective means of preventing the transduction and trans-
mission of nociceptive signals is through the use of local
anesthetics. Indeed, it is the authors’ opinion that the
only currently available analgesics that can completely
block perioperative pain are the local anesthetics. Des-
pite their potential efficacy, the relief provided by cur-
rently available local anesthetics is of limited duration,
and this may be one factor contributing to the currently
relatively low use of local anesthetics in small animal
practice [2]. Bupivacaine has the longest reported activ-
ity, potentially providing analgesia for as long as 6–7 h
[3–5]. However, currently the only method in veterinary
medicine to extend the action of bupivacaine beyond
this involves using a wound catheter, and instilling bupi-
vacaine approximately every 6 h into the wound [6, 7].
In 2011 the FDA approved an extended-release formu-
lation of bupivacaine, DepoFoam® bupivacaine1 for use
as a single-dose infiltration into the surgical site to effect
postsurgical analgesia in human surgical patients. The
DepoFoam technology used in this product consists of
multivesicular liposomes encapsulating aqueous bupiva-
caine. The liposomes are microscopic structures made of
nonconcentric lipid bilayers designed such that bupiva-
caine is gradually released from vesicles over 96 h as the
lipid bilayers break down. The lipids making up the bi-
layer structures consist of phospholipids, cholesterol and
triglycerides, and importantly do not contain lecithin
which has been associated with tissue necrosis and tox-
icity [8]. Bupivacaine liposome injectable suspension
(Depofoam bupivacaine) has been extensively studied in
dogs as part of the development for human use [9, 10].
Bupivacaine liposome injectable suspension, known as
AT-0032 is currently being investigated for use in veter-
inary patients. In a preliminary laboratory study to as-
sess the analgesic properties of AT-003 following tissue
infiltration around the site of stifle arthrotomy in beagle
dogs, a dose of 5.3 mg/kg was determined to provide
adequate analgesia for at least 24 h post-surgery
(unpublished data). The current report describes a pilot
field study evaluating the post-operative analgesia pro-
vided by AT-003 at a dose of up to 5.3 mg/kg adminis-
tered by tissue infiltration just prior to closure
following cranial cruciate ligament (CCL) surgery in
client-owned dogs, using subjective, in-clinic assess-
ments of pain.
We hypothesized that 5.3 mg/kg of bupivacaine lipo-
some injectable suspension would provide clinically ef-
fective analgesia, as measured using subjective clinical
assessment, over a 72-h period following stifle surgery in
dogs, when compared to a saline placebo.
Results
Three (3) investigative sites screened and enrolled cases.
There were forty-nine (49) dogs screened and forty-six
(46) dogs enrolled in the study over the period April
2014 to September 2014 and the study concluded when
the target number of dogs was enrolled. All forty-six
(46) dogs enrolled in the study were included in both
the efficacy and safety evaluation (see flow diagram,
Fig. 1). Twenty-four (24) dogs were treated with AT-003
and twenty-two (22) dogs with saline. The mean (range)
age was 7.47 years (2.1–13.3) for the AT-003 group and
6.71 years (1.0–10.4) for the saline placebo group. Group
characteristics are summarized in Table 1.
CMPS-SF scores
The mean total CMPS-SF scores (+/− SEM) at the base-
line (pre-surgery) evaluation were 1.58 (0.22) and 1.18
(0.20) for AT-003 and saline placebo, respectively. Fol-
lowing surgery, total CMPS-SF scores (Table 2) were
consistently lower at all post-operative time points (ex-
cept for 72 h) for the AT-003 treated dogs compared to
saline placebo treated dogs, with a significant overall
treatment effect (p = 0.0027) in favor of AT-003. At 72 h,
the scores were similar, but only two dogs remained in
the saline placebo group (note: at 60 h data were missing
from one placebo dog). There was no treatment by time
effect (p = 0.8041), however there were only a small
number of subjects remaining in the saline placebo
group after 12 h. When site effect and treatment by
site interaction were entered into the model, the
overall treatment effect was again statistically signifi-
cant (p = 0.0036), with lower CMPS-SF scores in the
AT-003 group.
Surgical site manipulation scores
The mean Surgical Site Manipulation Scores (SSMS)
(+/−SEM) at the baseline (pre-surgery) evaluation were
0.42 (0.1) and 0.68 (0.21) for AT-003 and saline placebo,
respectively. Following treatment, the mean scores for
AT-003 were less than those for placebo at each evalu-
ation time point except at 12, 54, 60 and 72 h (Table 3),
however, there were only two placebo dogs left in the
study at 54 h. The overall treatment effect showed no
statistically significant difference between treatment
groups (p = 0.0941), however when site effect and treat-
ment by site interaction were entered into the model,
the overall treatment effect was statistically significant
(p = 0.0312), with lower surgical site manipulation scores
in the AT-003 group.
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Success/Failure analysis
Dogs receiving AT-003 were more likely to remain in
the study (that is, not be rescued due to insufficient pain
relief ) following the surgical procedure than dogs receiv-
ing the saline placebo. At 72 h post-operatively, 9 of 24
AT-003 dogs and 2 of 22 placebo dogs remained in the
study. Overall treatment success at each time period was
statistically significantly different between the groups
(p = 0.0001 for 0-24 h; p = 0.0349 for 0–48 h; and p =
0.0240 for 0–72 h) with more dogs being designated
treatment successes in the AT-003 treatment group
compared to the saline placebo group in each time
period (Table 4). The odds of success were almost 13
times greater in the AT-003 group compared to the
placebo group in the first 24 h; 4.5 times greater
over the 0–48 h period, and 6 times greater over the
0–72 h period.
Adverse events
AT-003 appeared to be well tolerated. Adverse events
were reported in 5 dogs during the study, three in the
AT-003 group and two in the saline placebo group, all
from a single site. All were classified with an “unlikely”
or “unknown” relationship to study treatment. One dog
in the AT-003 treatment group had mild bradycardia
(heart rate was 56 beats per minute, as compared to 96
beats per minute at the pre-enrollment physical examin-
ation) detected 4 hours after surgery (at time of rescue).
Another dog in the AT-003 treatment group vomited on
a single occasion, and this resolved with no treatment. A
third dog in the AT-003 group was found to have a small
excoriated patch on its nose, considered unlikely to be
treatment related, and rather resulting from trying to
exit the cage. In the saline placebo group, a flea was
found on one dog, and another had an episode of diar-
rhea with fresh blood, which resolved without treatment.
Discussion
The study hypothesis was supported, with the results
indicating measurable analgesic effects of AT-003
(bupivacaine liposome injectable suspension) compared
to placebo, over a 72-h period following surgical site tis-
sue infiltration in 46 dogs undergoing cranial cruciate
ligament (CCL) surgery. The odds of success (in terms
Table 1 Per protocol population demographics of enrolled
dogs in the AT-003 and saline placebo groups
Characteristic AT-003 (n = 24) Saline placebo (n = 22)
Age (years) Mean 7.47 6.71
Min, Max 2.08, 13.33 1.00, 10.42
Weight (kg) Mean 26.54 22.57
Min, Max 3.2, 79.3 2.4, 44.8
Sex Female 0 0
Female spayed 13 11
Male 1 0
Male castrated 10 11
Fig. 1 Study participant flow diagram
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of not needing rescue) were dramatically greater in the
AT-003 group than the placebo group. It is possible that
some dogs may have been inappropriately designated as
comfortable when in fact pain was present, potentially
due to the carry-over effects of the acepromazine sed-
ation in the early postoperative period, or due to a lack
of sensitivity of the pain assessment tool. However, in
these respects, both groups should have been equally af-
fected, making the comparison valid.
Pain is difficult to measure, and although the assess-
ment tool used in the present study has been widely
used, it has never undergone criterion validation. How-
ever, one measure of the success in measuring pain in
placebo-controlled studies is the rescue rate in the
placebo group. In the current study, it was 77 % within
24 h, and 91 % over the 72 h of the study, suggesting in-
adequate pain relief was being detected, and giving one
further confidence that AT-003 provided clinically meas-
urable pain relief. If one assumes surgery is associated
with pain, then the lack of rescue of 2/22 dogs in the
placebo group would be considered a failure of the as-
sessment system. However, the approach to assessment
and rescue in our study appears to have been compara-
tively successful when looked at other published studies.
In a study of dogs undergoing cruciate surgery [11], only
11 % (1 of 9 dogs) was rescued in the 24 h following sur-
gery. In a study of dogs undergoing soft tissue surgery
[12], only 9 of 16 dogs were rescued over a 72-h period
Table 2 Total mean (SEM) CMPS-SF scores by treatment group and time point
Time point
(hours)
AT-003 Saline placebo
Number of
dogs evaluated
Mean (+/SEM) CMPS-SF Number of
dogs evaluated
Mean (+/−SEM)
CMPS-SF
0 24 1.58 (0.22) 22 1.18 (0.20)
2 24 4.38 (0.47) 22 6.82 (0.72)
4 22 3.36 (0.35) 16 6.56 (0.82)
8 21 4.24 (0.43) 9 7.00 (1.11)
12 19 4.21 (0.66) 5 6.20 (1.93)
24 14 3.50 (0.69) 4 4.50 (1.32)
30 11 2.64 (0.43) 3 5.67 (1.20)
36 10 2.20 (0.29) 3 3.33 (1.20)
48 10 2.30 (0.68) 3 4.67 (2.19)
54 9 2.44 (0.53) 2 3.00 (2.00)
60 9 2.00 (0.53) 1 5.00 (NA)
72 9 2.11 (0.48) 2 2.00 (0.00)
NA Not Applicable
Table 3 Total Mean (SEM) Surgical Site Manipulation Scores by Treatment Group & Time Point
Time point
(hours)
AT-003 Saline Placebo
Number of
dogs evaluated
Mean surgical site
manipulation (SEM)
Number of
dogs evaluated
Mean surgical site
manipulation (SEM)
0 24 0.42 (0.10) 22 0.68 (0.21)
2 24 1.13 (0.31) 22 2.32 (0.30)
4 22 0.95 (0.27) 16 2.56 (0.32)
8 21 1.33 (0.30) 9 2.11 (0.45)
12 19 1.47 (0.30) 5 1.40 (0.51)
24 14 1.43 (0.39) 4 1.50 (0.50)
30 11 0.82 (0.33) 3 1.67 (0.67)
36 10 0.70 (0.30) 3 1.00 (1.00)
48 10 0.90 (0.35) 3 1.00 (1.00)
54 9 0.67 (0.37) 2 0.00 (0.00)
60 9 0.33 (0.24) 1 0.00 (NA)
72 9 0.67 (0.29) 2 0.00 (0.00)
SEM standard error of the mean, NA not applicable
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postoperatively. The lack of intra-operative analgesia
provision (beyond preoperative hydromorphone, which
all dogs received) was very deliberate due to how difficult
pain is to measure. Given how insensitive our current as-
sessment tools are, the more background treatments that
are administered, the more difficult it becomes to assess
whether a novel analgesic provides any benefit. Future
work, hopefully with more sensitive, and ideally objective,
outcome assessments, could evaluate the effect size of this
product versus other treatments.
There are few data as to how long post-surgical pain
persists in animals, and this time period will vary with
the type of surgical procedure performed. The recom-
mended time period for administration of analgesics
post-operatively varies from days to weeks, depending
on the surgery performed, but expert opinion empha-
sizes the first 72 h following surgery as a critical time
period when analgesics should be administered [13].
Post-surgical pain can generally be well controlled while
an animal is hospitalized using injectable opioids, keta-
mine, cyclooxygenase inhibiting NSAIDs and local anes-
thetics. However, with most veterinary patients being
discharged from the veterinary hospital the same day, or
within 24 h following surgery, there is a need to bridge
between analgesics provided in the hospital and effective
pain relief in the home environment. Currently in the
United States, only oral cyclooxygenase inhibiting
NSAIDs and transdermal fentanyl liquid3 have been
approved for post-surgical analgesia in dogs. Beyond
these options, there are unapproved fentanyl patches
manufactured for human use, which have been sug-
gested to be efficacious [14] and tramadol is widely
used, despite little evidence of efficacy [15–18].
Overall, there is a clear unmet need for effective anal-
gesic products that can be administered in the clinic,
and provide pain relief for the crucial first few days
following surgery in the home environment. This pilot
study suggests that bupivacaine liposome injectable sus-
pension may directly address this unmet need, providing
up to 72 h of analgesia. Though statistically greater than
placebo, not all of the AT-003 dogs were successes out
to 72 h. In this study, surgeons were not instructed to
infiltrate around the anchor points of the suture
material. In future studies, infiltration into all the tissue
layers as well as around the anchor points for suture or
around implants will be performed. Bupivacaine lipo-
some injectable suspension will need to be administered
as part of a multimodal approach as the anesthetic wears
off, and indeed, this is consistent with the current rec-
ommendations for the treatment of postoperative pain
[19, 20]. The prolonged duration of continuous action
may also prevent episodes of breakthrough pain.
The current study was a pilot study, performed in dogs
undergoing a single type of surgery, lateral retinacular
suture placement for cruciate insufficiency. As such, the
generalizability of these results to the larger population
of dogs undergoing a variety of orthopedic surgeries and
other surgical procedures is unknown. However, given
the demonstrated efficacy in human clinical studies in
both orthopedic [21] and soft tissue [22] surgery, it is
highly likely that AT-003 will prove efficacious in dogs
undergoing a wide variety of surgical procedures.
The current study employed direct injection of bupiva-
caine liposome injectable suspension into the surgical
wound, and this may raise concerns about wound heal-
ing and wound infection. While there is some evidence
that local anesthetics alter the cellular events of early tis-
sue healing, there does not appear to be a clinically sig-
nificant impact on wound healing or mechanical wound
strength in preclinical animal studies [23] or humans.
Infection rates following continuous local anesthetic in-
stallation into wounds found that reported wound infec-
tion rates were similar between active (0.7 %) and
control groups (1.2 %) in humans undergoing surgery
[24]. In the present study, no wound related adverse ef-
fects were seen, which mirrors the extensive pre-clinical
work in dogs that has been performed with this product.
In a dog model of inguinal hernia repair, bupivacaine
liposome injectable suspension was infiltrated into the
surgical site at doses ranging from 9 to 25 mg/kg and a
mild granulomatous inflammatory response was seen
histologically, that had not resolved by 2 weeks following
infiltration, but was not considered indicative of any
adverse effect on wound healing and the wound healing
findings were similar to control (saline or bupivacaine
HCL) treated animals [9]. In the present study, one dog
Table 4 Summary results of the success/failure analysis. Dogs deemed failures in one time period were carried forward into the next
time period, where they were also categorized as failures. The Odds of success (and 95 % Confidence Interval, CI) are tabulated
Time interval AT-003 Saline placebo Chi-square p-value Odds ratio
0–24 h Success 19 (79.2 %) 5 (22.7 %) 0.0001 12.92 (3.18, 52.48)
Failure 5 (20.8 %) 17 (77.3 %)
0–48 h Success 10 (41.7 %) 3 (13.6 %) 0.0349 4.52 (1.05, 19.54)
Failure 14 (58.3 %) 19 (86.4 %)
0–72 h Success 9 (37.5 %) 2 (9.1 %) 0.0240 6.0 (1.13, 31.94)
Failure 15 (62.5 %) 20 (90.9 %)
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was found to have bradycardia 4 h following administra-
tion of AT-003. In previous work, repeated doses of
bupivacaine liposome injectable suspension were admin-
istered to dogs and the dogs evaluated for cardiotoxicity
[25]. Doses of 9, 18 and 30 mg/kg bupivacaine liposome
injectable suspension, 9 mg/kg bupivacaine HCl, or a
volume-equivalent dose of saline, were administered into
the subcutaneous tissue over the scapulae twice weekly
for 4 weeks. No clinical signs consistent with central
nervous system toxicity were seen and no electrocar-
diogram abnormalities were detected [25].
Dilution in this study was allowed based on the human
experience and volumes used in previous canine knee
surgery studies. Dilution does not impact efficacy in
humans [26], and that appeared to be the case in this
study as well. Most surgeons administered the drug in
the undiluted state. The one surgeon who did dilute did
so such that the total volume was divisible by four, facili-
tating a 25, 50 and 25 % tissue infiltration distribution.
Conclusions
Further work is indicated to develop this product for
clinical use. This product has significant potential to
address an important clinical need - the provision of
extended duration local wound analgesia.
Methods
Design
The study was a masked, randomized, placebo-controlled,
multi-center pilot field study, conducted under Good
Clinical Practice Guidelines. The study was performed as
part of the development program of AT-003 for FDA
approval in dogs. The study was conducted according to
the protocol and in compliance with Good Clinical
Practice (VICH) Guideline GL9, International Cooper-
ation on Harmonization of Technical Requirements for
Registration of Veterinary Medicinal Products (VICH),
June 2000, and the FDA Center for Veterinary Medicine
(CVM) Guidance for Industry #85, May 2001. The study
protocol was approved by Aratana’s internal review board.
Each owner gave written informed consent prior to dogs
being enrolled into the study, and best practices for
veterinary care and patient management were followed
throughout the study.
Study population
Owned pet dogs of any breed or gender, greater than
5 months of age, deemed to require surgery for cruciate
ligament insufficiency, were recruited to the study.
Inclusion criteria
Dogs were required to have been diagnosed with cranial
cruciate ligament insufficiency within the previous
4 months, and not to have received systemic anti-
inflammatories within 7 days of the surgical procedure.
Dogs of a fractious demeanor, or who had an uncon-
trolled endocrine or systemic disorder, or who had had
surgery within the previous 14 days were not eligible.
Study protocol overview
The study evaluated the post-operative analgesia pro-
vided by AT-003 at a dose of 5.3 mg/kg administered by
tissue infiltration just prior to closure following unilat-
eral cranial cruciate ligament (CCL) surgery in dogs.
The study protocol is outlined in Fig. 2. Dogs were ran-
domly assigned to one of the two treatment groups and
AT-003 (5.3 mg/kg) or saline placebo (1.0 mL/kg) was
administered into the wound bed at the end of surgery,
prior to and during closure of the wound. Both AT-003
and saline were injected directly into tissues, using a
moving needle technique.
All dogs underwent the lateral retinacular suture
procedure, including stifle arthrotomy. The primary
outcome measure was the Glasgow Composite Meas-
ure Pain Scale (CMPS-SF). Assessments were per-
formed prior to premedication/surgery following a 2-h
acclimation period, and at 2, 4, 8, 12, 24, 30, 36, 48,
54, 60 and 72 h following surgery by veterinarians
and veterinary technicians trained on the use of the
CMPS-SF. After the CMPS-SF assessment was com-
pleted, a Surgical Site Manipulation Score (secondary
outcome measure) was assessed by standardized ma-
nipulation of the stifle joint that had undergone sur-
gery (Table 5). Dogs were administered rescue
analgesia (choice of rescue was at the discretion of
the veterinarian) if the CMPS-SF score was greater
than 8 or if the assessors felt additional analgesia was
needed. Following either of these, dogs were removed
from the study. Everyone involved in the assessments
was trained in the use of the assessment tools
through explanation and discussion of the tools dur-
ing a single ‘classroom’ style training session run by
the Contract Research Organization, and the docu-
ment describing the definitions of expressions used in
the CMPS-SF. All assessors had prior experience of
using the CMPS-SF in clinical studies. No more than
3 assessors were permitted to do the assessments on
any one dog. Different sites were not calibrated on
the use of the CMPS-SF, and nor were any measures
put in place to confirm consistency of scoring.
Safety assessments (secondary outcome measures)
were made using clinical observations and behavioral
observations at all assessment time points, and physical
examination findings at 72 h or following rescue. No
specific guidance on what to look for in the clinical ob-
servations was given; the physical examination was a
standard physical examination covering evaluation of all
body systems. Owners were also called within 4–7 days
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following surgery to capture any adverse events that oc-
curred following discharge.
Anesthetic protocol
Acepromazine (0.05 mg/kg) was administered intraven-
ously (IV) or intramuscularly (IM) with a maximum
total dose of 3.0 mg regardless of body weight. The
doses of acepromazine used in the study were based on
our experience with the drug. At least 15 min after ace-
promazine administration, hydromorphone (0.1 mg/kg)
was administered IV. Anesthesia was induced with pro-
pofol, and maintained on isoflurane carried in oxygen,
delivered via an endotracheal tube and a rebreathing cir-
cuit. Additional local/regional anesthesia (epidural, nerve
block, intra-articular etc.) was not permitted, nor were
any other analgesics. Fluids were administered intraven-
ously during anesthesia.
Randomization to treatment groups
Dogs were randomly assigned to one of the two treat-
ment groups and treated post-CCL surgery with AT-003
(5.3 mg/kg, equivalent to 0.4 mL/kg) or saline (1.0 mL/
kg). Surgeons were allowed to dilute AT-003 up to 15
times, if needed, in order to cover the surgical area, with
a recommended volume of 0.4–1.0 mL/kg based on pre-
vious studies. Randomization was performed using the
Prelude Dynamics VISION™ electronic data capture
(EDC) system. The VISION randomization framework
generated each random treatment from a pre-computed
table of treatments for each site. The randomization cal-
culation maintained equal size groups per site and was
calculated based on the current patient population. Sub-
jects were randomized in blocks of two, stratified by site.
Masking procedures
One individual at each site was designated the Dispenser,
and they documented the assignment of dogs to treat-
ment group and kept the related documentation in a se-
cure site, away from all other personnel. The Dispenser
and the veterinarian performing the surgery had know-
ledge of which treatment group each dog was assigned.
Blinded personnel were not given access to the treat-
ment or randomization forms. The veterinarian or
trained technician performing the assessments, sponsor,
statistician and any other personnel involved in clinical
evaluations and observations remained blinded to treat-
ment during the study and until data base lock. The
Owners were also blinded to treatment.
Tissue infiltration procedure
AT-003 or saline was injected slowly into the tissues
using a 1–1.5 in. long needle, using a ‘moving needle
technique’, in which the needle is inserted to near the
hub and the material is injected as the needle is pulled
out. The needle is inserted at varying angles depending
on how the tissue is best approached in order to deposit
the injectate within the tissues. In general, this means
inserting the needle approximately parallel to the surface
of the skin. The injections are repeated to create an area
of infiltrated tissue around the whole wound, and at all
levels of the wound. Approximately 25, 50 and 25 % of
the AT-003 or saline was injected into the tissues around
the joint capsule, the fascial tissue, and the sub-cuticular
tissue, respectfully. The injections were performed such
that the whole wound, at all levels, was infiltrated with
AT-003 or saline. Dilution of AT-003 with normal saline
was permitted and was utilized for 12 of the AT-003
treated dogs, all at one site, with a maximal dilution of
1:1 AT-003 to saline.
Fig. 2 Study Protocol Outline
Table 5 Surgical Site Manipulation scoring system. At each
relevant assessment time point, the joint was gently palpated
around the surgical incision, and then the joint was put through
a passive range of motion, flexing and extending the joint
Manipulate the joint through a normal range of motion, and score the
patient as per below:
Score Response
0 Does not notice manipulation.
1 Orients to site on manipulation, does not resist.
2 Orients to site, may lick, slight objection to manipulation
3 Withdraws from manipulation, may vocalize, excessive licking
4 Tries to escape from manipulation, or prevent manipulation,
may bite or show aggression.
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Outcome measures
The primary outcome measure was the Glasgow Com-
posite Measure Pain Scale (Short Form) (CMPS-SF), and
secondary outcome measures were a Surgical Site Ma-
nipulation Score and an evaluation of adverse events.
CMPS-SF
The Glasgow Composite Measure Pain Scale-Short
Form (CMPS-SF), (http://www.newmetrica.com/acute-
pain-measurement/download-short-form-painquestion
naire-for-dogs/) is a subjective clinical metrology in-
strument used by animal caretakers to evaluate peri-
operative pain in a practice setting that was developed at
the University of Glasgow, UK [27, 28]. The expressions
used in the CMPS-SF were defined in order to assist in
training of sites, and are detailed in Additional file 1. Data
were captured electronically, and thus the electronic ver-
sion of the CMPS-SF differed from the published paper
version. The layout of the electronic version is illustrated
in Additional file 2: Figure S1.
Surgical site manipulation score (SSMS)
A simple descriptive scale, scored on a 0–4 scale
(Table 5) was used for the assessment of surgical site
pain associated with cruciate surgery. The scale was con-
structed by one of the authors, and is similar to wound
palpation scoring systems used previously [7].
Adverse events
An adverse event was defined as any observation, un-
desirable experience, reaction or side effect in animals
that was unfavorable and unintended and occurred after
the use of AT-003 or placebo, whether or not considered
to be treatment related. A serious adverse event was de-
fined as any adverse event that resulted in death, was
life-threatening, or resulted in persistent or significant
disability/incapacity, although no serious adverse event
occurred during this study.
Rescue analgesia
Dogs were removed from the study and administered
rescue analgesia if the CMPS-SF score at a designated
assessment time point was greater than 8 or at any time
(assessment time point or at any time in between) if the
assessing veterinarian felt additional analgesia was
needed. The intervention score of 8 was based on one
investigator’s (BDXL) experience with the CMPS-SF, and
a lack of data to substantiate the suggestion of an interven-
tion score of 6 (http://www.newmetrica.com/acute-pain-
measurement/download-short-form-painquestionnaire-for-
dogs/). No dog in the study was removed for a reason other
than rescue analgesia.
Data capture
Most data were captured electronically using an elec-
tronic data capture (EDC) system VISION developed
and supported by Prelude Dynamics, LLC.
Power analysis and statistical analysis
The enrollment target was at least 40 evaluable cases (20
AT-003 and 20 placebo) per the study randomization
schedule across all sites. An evaluable sample size of 20
AT-003 and 20 placebo cases was determined to be able
to provide more than 90 % power (alpha = 0.05, 2-sided)
to detect a difference between treatment groups of 0.37
(pooled standard deviation = 0.30) in the CMPS-SF as-
sessment at 24 h post-administration. These calculations
were based on results from a preliminary laboratory
study to assess the analgesic properties of AT-003 fol-
lowing tissue infiltration around the site of stifle arthrot-
omy in beagle dogs.
To be eligible for the statistical analysis, each site
must have enrolled and completed a minimum of 2
evaluable cases (at least 1 of each treatment). For
total CMPS-SF and Surgical site manipulation scores,
repeated measures analysis of variance were utilized
to test for possible differences between treatment
groups. SAS/STAT Proc MIXED were implemented
with the model containing terms for treatment
group, time point and the interaction of treatment by
time point. The baseline value was included in the
model as a covariate. If the treatment group by time
point interaction was found to be statistically signifi-
cant, then treatment effects were evaluated for each
time point. The covariance structure that provided
the smallest Akaike’s Information Criterion value was
used. Covariance structures that were tested include
Compound Symmetry (CS), heterogeneous CS (CSH),
first-order autoregressive [AR(1)] and heterogeneous
autoregressive [ARH(1)]. Additionally, exploratory analysis
used a repeated measures analysis of variance that
included site effect and treatment by site interaction in
the model.
A success/failure analysis was also employed, with suc-
cess defined as no pain intervention over the intervals of
0–24 h, 0–48 h and 0–72 h. The number and percentage
of dogs that were a success were presented for each time
interval by treatment group. The chi-square test was uti-
lized to test for possible differences between treatment
groups, and odds ratios described.
Endnotes
1Exparel, Pacira Pharmaceuticals, Inc., Parsippany, NJ.
2Nocita, Aratana Therapeutics, Inc., Leawood, KS.
3Recuvyra™, Elanco.
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Additional files
Additional file 1: Definitions of the expressions used in the CMPS-SF.
In order to facilitate consistency in the way the CMPS-SF was used, the
expressions used in the CMPS-SF were defined, and this file contains
those definitions. (DOCX 102 kb)
Additional file 2: Figure S1. Layout of the electronic version CMPS-SF.
The electronic version CMPS-SF differed from the published paper
version, and the layout of the electronic version is shown in this
Additional file. (TIFF 5625 kb)
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